Harnessing Data on New and Emerging Therapies for Personaliz -

Thank you for attending.
Please click "Next Page" to proceed. To obtain credit, you must complete the posttest, evaluation, and proceed to the claim credit page.

Note for ODs: COPE guidelines dictate that in order to receive credit, learners must remain logged in to the synchronous virtual activity until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.

Scroll back to top

Details

Overview
Recently, several new dry eye disease therapies have been approved by the FDA and studies comparing various therapies have been published. Join Program Chair Laura M. Periman, MD; Mile Brujic, OD, FAAO; and Jessica Steen, OD, FAAO, to learn about these as well as the pipeline.
Note About Obtaining COPE Credit:
You must attend the course in its entirety.
COPE guidelines dictate that in order to receive credit, learners must remain present at the synchronous virtual symposium until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
This activity is supported by an unrestricted educational grant from Oyster Point.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Discuss pharmacologic therapies approved and in the pipeline for the treatment of dry eye disease, their known mechanism of action, and potential applications
- Compare the known safety, efficacy, tolerability data of pharmacologic therapies and therapeutic devices approved for dry eye disease
- Create personalized care plans for patients with dry eye disease tailored to the risk-benefit profile of the treatment, specific signs and symptoms, and other patient-level factors based on the latest evidence
Accreditation
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Evolve Medical Education, LLC is a COPE-accredited administrator.
This activity, COPE Activity Number 126679 is accredited by COPE for continuing education for optometrists. This course is approved for 1.0 hour of CE.
Course #: 86492-TD
Activity #: 126679
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
Laura M. Periman, MD
Founder, Director
Dry Eye Services and Clinical Research
Periman Eye Institute
Seattle, WA

Mile Brujic, OD, FAAO
Premier Vision Group
Bowling Green, OH

Jessica Steen, OD, FAAO
Associate Professor
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Laura M. Periman, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Alcon, Aldeyra, Allergan/AbbVie, Avellino, Azura, Bausch + Lomb, Bruder, Dompé, Eyedetec, Eyevance, Horizon, Kala Pharmaceuticals, Lumenis, Myze, Novartis, Nusight Medical, Quidel, Santen, ScienceBased Health, Scope, Sun Pharma, Tarsus, ThermaMEDx, Verséa, and Visant. Consultant: Aerie Pharmaceuticals, Alcon, Aldeyra, Allergan/AbbVie, Azura, Bausch + Lomb, Eyevance, Horizon, Kala Pharmaceuticals, Lumenis, Myze, Novartis, Nusight Medical, Olympic Ophthalmics, Quidel, Santen, ScienceBased Health, Scope, Sun Pharma, Tarsus, ThermaMEDx, and Visant. Grant/Research Support: Aerie Pharmaceuticals, Alcon, Bausch + Lomb, Kala Pharmaceuticals, Lumenis, Mark Abelson, MD, Novartis, Olympic Ophthalmics, Oyster Point Pharma, and Tarsus. Speaker's Bureau: Alcon, Allergan/AbbVie, Bausch + Lomb, Eyevance, Kala Pharmaceuticals, Lumenis, Mallinkrodt, Novartis, Nusight Medical, Olympic Ophthalmics, Quidel, Santen, ScienceBased Health, Scope, Sun Pharma, and Tarsus. Stock/Shareholder: Eyedetec, Myze, Quench Method, Verséa, and Visant.
Mile Brujic, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of speaking, writing, participating in an advisory capacity, research or meeting support from: ABB Optical, Alcon, Aldeyra, Allergan, Art Optical Apellis Pharmaceuticals, Avellino, Bausch + Lomb, Contamac, CooperVision, CSEye, Dompé, Horizon, Johnson & Johnson, Lenstech, Notaal Vision, Novartis, Oyster Point Pharma, Quidel, Radius XR, RVL, Santen, Sun Pharma, Tangible Science, Tarsus, Visionix, Visus, Walman Optical and Zea Vision.
Jessica Steen, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Bausch + Lomb, Ocuphire Pharma, OcuTerra, Peripherex, Santen, and Théa Pharma. Shareholder: Clearside Biomedical. Speaker's Bureau: Bausch + Lomb, Carl Zeiss Meditec, Oyster Point Pharma, and Théa Pharma.
The Evolve staff, planners, and reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Oyster Point.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Note About Obtaining COPE Credit:
You must attend the course in its entirety.
COPE guidelines dictate that in order to receive credit, learners must remain present at the synchronous virtual symposium until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 09/29/2023

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Title

Share on ReachMD